

Secondary Progressive Multiple Sclerosis

Disease overview, Epidemiology and Drug
overview

Pharmascroll

Table of Contents

1. Multiple Sclerosis Definition.....	4
2. Types of Multiple Sclerosis.....	6
a. Relapsing Remitting MS.....	6
b. Secondary Progressive MS.....	6
c. Primary Progressive MS.....	7
d. Progressive Relapsing MS.....	7
3. Secondary Progressive Relapsing MS Defined.....	8
4. Causes of SPMS.....	11
5. Profile of SPMS Patient.....	12
6. Symptoms of SPMS.....	13
7. Disease progression and impact on QoL.....	15
8. Disease Diagnosis.....	16
a. Disease diagnosis through symptoms.....	16
b. Disease diagnosis through medical tests.....	17
9. Disease Epidemiology.....	19
a. US Epidemiology.....	19
b. UK Epidemiology.....	20
c. Germany Epidemiology.....	21
d. Italy Epidemiology.....	22
e. France Epidemiology.....	23
f. Spain Epidemiology.....	24

- g. Japan Epidemiology.....25
- 10. Factors impacting a physician’s prescription decision.....26
 - a. Efficacy.....27
 - b. Tolerability and Safety.....29
 - c. Monitoring Requirements.....32
 - d. Pricing and Reimbursement.....34
- 11. Disease Modifying Therapies for SPMS.....35
 - a. Laquinimod.....35
 - i. About the Product.....35
 - ii. Patent and Trial Details.....36
 - iii. Impact of Laquinimod.....38
 - b. Lemtrada.....39
 - i. About the Product.....39
 - ii. Patent and Trial Details.....40
 - iii. Impact of Lemtrada.....41
 - c. Masitinib.....42
 - i. About the Product.....42
 - ii. Patent and Trial Details.....43
 - iii. Impact of Masitinib.....44
 - d. Ocrelizumab.....45
 - i. About the Product.....45
 - ii. Patent and Trial Details.....46
 - iii. Impact of Ocrelizumab.....48

- e. Tysabri.....49**
 - i. About the Product.....49**
 - ii. Patent and Trial Details.....50**
 - iii. Impact of Tysabri.....51**
- f. Siponimod.....52**
 - i. About the Product.....52**
 - ii. Patent and Trial Details.....53**
 - iii. Impact of Siponimod.....54**
- g. Zinbryta.....55**
 - i. About the Product.....55**
 - ii. Patent and Trial Details.....56**
 - iii. Impact of Zinbryta.....57**
- h. Mitoxantrone.....58**
 - i. About the Product.....58**
 - ii. Patent and Trial Details.....59**
 - iii. Impact of Mitoxantrone.....60**
- i. Ponesimod.....61**
 - i. About the Product.....61**
 - ii. Patent and Trial Details.....62**
 - iii. Impact of Ponesimod.....63**